DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,060,524 | -30.1% | 99,880 | 0.0% | 0.04% | -27.6% |
| Q2 2023 | $2,947,459 | +28.1% | 99,880 | 0.0% | 0.06% | +11.5% |
| Q1 2023 | $2,301,235 | -17.2% | 99,880 | 0.0% | 0.05% | -20.0% |
| Q4 2022 | $2,777,663 | -9.4% | 99,880 | 0.0% | 0.06% | -19.8% |
| Q3 2022 | $3,065,000 | +4.3% | 99,880 | 0.0% | 0.08% | +14.1% |
| Q2 2022 | $2,939,000 | -8.5% | 99,880 | 0.0% | 0.07% | +1.4% |
| Q1 2022 | $3,213,000 | -27.9% | 99,880 | 0.0% | 0.07% | -27.1% |
| Q4 2021 | $4,455,000 | -11.7% | 99,880 | -0.1% | 0.10% | -17.9% |
| Q3 2021 | $5,045,000 | -16.7% | 100,000 | +29.5% | 0.12% | -16.4% |
| Q2 2021 | $6,056,000 | +86.1% | 77,200 | +35.4% | 0.14% | +57.3% |
| Q1 2021 | $3,255,000 | +159.2% | 57,000 | +280.0% | 0.09% | +111.9% |
| Q4 2020 | $1,256,000 | – | 15,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |